Entropy Technologies LP Takes $656,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Entropy Technologies LP bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the third quarter, Holdings Channel reports. The institutional investor bought 5,980 shares of the medical equipment provider’s stock, valued at approximately $656,000.

A number of other large investors also recently modified their holdings of LNTH. GAMMA Investing LLC lifted its holdings in shares of Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 208 shares in the last quarter. Signaturefd LLC lifted its holdings in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares in the last quarter. Nkcfo LLC bought a new stake in Lantheus during the second quarter worth $47,000. UMB Bank n.a. lifted its holdings in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 126 shares during the period. Finally, Kathleen S. Wright Associates Inc. bought a new stake in Lantheus during the third quarter worth $51,000. Institutional investors own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. Truist Financial reiterated a “buy” rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities dropped their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a report on Friday, November 8th. Finally, B. Riley lifted their price target on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and an average price target of $122.50.

Lantheus Price Performance

Shares of LNTH opened at $80.84 on Friday. The firm has a market cap of $5.62 billion, a PE ratio of 13.45 and a beta of 0.51. The stock’s fifty day moving average price is $105.46 and its two-hundred day moving average price is $96.17. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.